Loading
Life sciences · Journal article
Frontiers in Pharmacology · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cervical cancer remains a predominant malignancy of the female reproductive system and a critical global health challenge. Traditional platinum-based agents such as cisplatin, carboplatin, and oxaliplatin, are cornerstones in postoperative adjuvant therapy, management of locally advanced cases, and systemic treatment of recurrent/metastatic disease. However, their clinical efficacy is frequently hampered by severe systemic toxicities and the emergence of chemoresistance. To address these bottlenecks, diverse nano-delivery platforms have been engineered to enhance bioavailability and mitigate adverse effects. This review systematically delineates the evolution of first-to third-generation platinum drugs, elucidating their molecular mechanisms of action specifically within the landscape of cervical cancer. Furthermore, we critically evaluate the clinical application of these agents and provide a comprehensive synthesis of recent advances in nano-delivery systems, including targeted and stimuli-responsive carriers. By bridging traditional pharmacology with cutting-edge nanotechnology, this review offers strategic insights into achieving precise delivery and controlled release, potentially defining new paradigms for the next-generation of cervical cancer therapeutics.